Telomir Pharmaceuticals, Inc. (TELO) Shareholder Equity
- 2026-06-30: Additional Paid in CapitalUSD $48.76M; Retained Earnings (Accumulated Deficit)USD $-43.72M; Stockholders' Equity Attributable to ParentUSD $5.03M; APIC, Share-based Payment Arrangement, Option, Increase for Cost RecognitionUSD 3 month · $587.74K.
- 2026-03-31: Additional Paid in CapitalUSD $46.96M; Retained Earnings (Accumulated Deficit)USD $-42.00M; Stockholders' Equity Attributable to ParentUSD $4.96M; APIC, Share-based Payment Arrangement, Option, Increase for Cost RecognitionUSD (m).
- 2025-12-31: Additional Paid in CapitalUSD $46.92M; Retained Earnings (Accumulated Deficit)USD $-41.01M; Stockholders' Equity Attributable to ParentUSD $5.91M; APIC, Share-based Payment Arrangement, Option, Increase for Cost RecognitionUSD (m).
- 2025-09-30: Additional Paid in CapitalUSD $45.93M; Retained Earnings (Accumulated Deficit)USD $-38.95M; Stockholders' Equity Attributable to ParentUSD $6.98M; APIC, Share-based Payment Arrangement, Option, Increase for Cost RecognitionUSD (m).
Telomir Pharmaceuticals, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $48.76M | $-43.72M | $5.03M | 3 month · $587.74K | 3 month · $198.73K | (m) |
| 2026-03-31 | $46.96M | $-42.00M | $4.96M | (m) | 3 month · $39.80K | (m) |
| 2025-12-31 | $46.92M | $-41.01M | $5.91M | (m) | 12 month · $5.29M | (m) |
| 2025-09-30 | $45.93M | $-38.95M | $6.98M | (m) | 3 month · $98.14K | (m) |
| 2025-06-30 | $38.33M | $-37.85M | $481.22K | (m) | 3 month · $3.82M | (m) |
| 2025-03-31 | $32.62M | $-32.78M | $-161.10K | (m) | 3 month · $1.38M | (m) |
| 2024-12-31 | $31.24M | $-30.60M | $643.04K | (m) | 12 month · $6.87M | (m) |
| 2024-09-30 | $28.14M | $-27.70M | $442.07K | (m) | 3 month · $4.81M 9 month · $4.81M | (m) |
| 2024-06-30 | $23.34M | $-21.77M | $1.63M | (m) | (m) | (m) |
| 2024-03-31 | $23.34M | $-20.32M | $3.02M | (m) | (m) | (m) |
| 2023-12-31 | $17.50M | $-14.06M | $3.44M | (m) | (m) | 12 month · $5.95M |
| 2023-09-30 | (m) | (m) | $2.18M | (m) | (m) | 9 month · $5.95M |
| 2023-06-30 | (m) | (m) | $3.89M | (m) | (m) | 3 month · $5.95M 6 month · $5.95M |
| 2023-03-31 | (m) | (m) | $-510.21K | (m) | (m) | (m) |
| 2022-12-31 | $55.00K | $-992.28K | $-937.28K | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $-138.13K | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |